TMThea Otto Mattsson

Thea Otto Mattsson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thea Otto Mattsson has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Anders Green

    OPEN – Open Patient data Explorative Network, Department of Clinical Research, University of Southern Denmark, and Odense University Hospital, Odense, Denmark

    1 shared publication
  • Anton Pottegård

    Department of Public Health, Division of Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense, Denmark

    1 shared publication
  • Anton Pottegård

    Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark Odense Denmark

    1 shared publication
  • B. Holm

    Department of Oncology, Herlev Hospital, Copenhagen

    1 shared publication
  • C.ø. Christensen

    Department of Oncology, Hospital Sønderjylland, Sønderborg, Denmark

    1 shared publication
  • Christina Louise Lindhart

    University College Absalon, Naestved, Denmark

    1 shared publication

Latest Publications

  • Open Access

    Professional Roles in Danish Clinics for General Late Effects After Cancer—A Qualitative Study

    by K. B. Dieperink, R. Skøtt, T. Mattsson, L. B. Thisted, C.ø. Christensen, L. K. Tolstrup

    Late effect clinics (LECs) post-primary cancer treatment emerge. We explored healthcare professionals’ experiences working in Danish LECs from a psychodynamic perspective seeking to understand how professionals from different disciplines navigate their roles and collaborate within the context of survivorship care. We employed a qualitative approach through three virtual focus groups with nurses, physicians, and psychologists n = 15. All respectively working in five different LECs with patients and caregivers affected by general late effects after cancer treatment. Data were analyzed using thematic analysis. Four themes were found: Transformation towards person-centered care, therapeutic space as a precondition, redefined professional boundaries, and challenges due to traditional hospital structures. The themes revealed that patients with late effects and their caregivers require a bio-psychosocial and person-centered approach, with an emphasis on creating a therapeutic space as a prerequisite for cooperation. The professionals were willing to expand their professional boundaries but were challenged by systemic hierarchy and the constant need for competency and team development. Experiences and dynamics within professional roles in Danish LECs have significant implications for rethinking the organization and professional development of care. These insights suggest the need to empower healthcare professionals, adapt to evolving professional roles, and enhance person-centered care in this unique survivorship context. Improved collaboration across roles could provide survivors with more cohesive, supportive care, though traditional hospital hierarchies pose challenges. Increased professional development promises a higher level of tailored, competent care for addressing complex late effects during survivorship.

  • End-of-life anticancer treatment – a nationwide registry-based study of trends in the use of chemo-, endocrine, immune-, and targeted therapies

    by Thea Otto Mattsson, Anton Pottegård, Trine Lembrecht Jørgensen, Anders Green, Mette Bliddal

    Anticancer treatments near the end of a patient’s life should generally be avoided, as it leaves the patient with no significant anticancer effect but increases the risk of severe side effects. We ...


  • Patient self‐testing of white blood cell count and differentiation: A study of feasibility and measurement performance in a population of Danish cancer patients

    by Thea Otto Mattsson, Christina Louise Lindhart, Jonas Schöley, Lennart Friis‐Hansen, Jørn Herrstedt

    Objective: Patients in anticancer treatment with a known side effect of neutropenia are monitored closely with laboratory measurements of white blood cell count (WBC) and differentiation. This study sought to evaluate measurement properties and feasibility of patients' self‐testing using a point‐of‐care testing (POCT) device.Methods: A prospective feasibility and measurement study comparing the standard measurement of cancer patients' WBC and neutrophil count with POCT measurements. The study included 60 outpatients and 22 inpatients from a department of oncology at a university hospital.Results: Patients successfully conducted 106 measurements using the POCT device. 46% of the patients were >70 years. Weighted Deming regression analysis showed minimal yet significant proportional bias between methods, with POCT increasingly underestimating both total WBC and neutrophils compared with the standard method the higher the count. Over 90% of patients reported they were willing and considered themselves able to use the POCT device at home.Conclusions: The instrument can be used for self‐testing of post‐anticancer leukopenia and has sufficient measurement precision for patient risk stratification. Patients are able and willing to conduct measurements including when in a situation of acute illness. Further studies are needed to confirm safety and value within patients’ own home.


  • Patient Involvement in Evaluation of Safety in Oral Antineoplastic Treatment: A Failure Mode and Effects Analysis in Patients and Health Care Professionals

    by Thea Otto Mattsson, Henriette Lipczak, Anton Pottegård

    Objectives: To identify risks associated with delivery of treatment with oral antineoplastic agents in an outpatient setting and to evaluate additional value and feasibility of engaging patients in a proactive risk analysis. Methods: We conducted 2 separate but parallel failure mode and effects analyses (FMEAs) among patients and health care professionals (HCPs) at a clinical oncology department in Denmark. Comparative analyses were performed using the FMEA process maps and risk priority numbers (RPNs) as main outcome measures. The FMEAs were augmented by semistructured interviews with HCPs and patients on acceptability and feasibility of FMEAs analyzed using systematic text condensation. Results: Patients and HCPs found failures in information regarding treatment (cause, aim, and plan) to be of high risk. Also, HCPs found failures in checking for potential interactions to be of high risk. HCPs focused on the in-hospitals procedures, whereas patients identified risks related to both the hospital and the home setting. Both HCPs and patients found participation in the FMEA process meaningful but found the use of RPNs difficult. Conclusions: Patient engagement in proactive risk analysis using FMEA is acceptable, meaningful, and feasible, with patients providing a different perspective on the risks associated with oral antineoplastic treatment compared with HCPs.


  • Non-intercepted dose errors in prescribing anti-neoplastic treatment: a prospective, comparative cohort study

    by T. O. Mattsson, B. Holm, H. Michelsen, J. L. Knudsen, K. Brixen, J. Herrstedt

    The incidence of non-intercepted prescription errors and the risk factors involved, including the impact of computerised order entry (CPOE) systems on such errors, are unknown. Our objective was to determine the incidence, type, severity, and related risk factors of non-intercepted prescription dose errors. A prospective, comparative cohort study in two clinical oncology units. One institution used a CPOE system with no connection to the electronic patient record system, while the other used paper-based prescription forms. All standard prescriptions were included and reviewed. Doses were recalculated according to the guidelines of each institution, using the patient data as documented in the patient record, the paper-based prescription form, or the CPOE system. A non-intercepted prescription dose error was defined as ≥10% difference between the administered and the recalculated dose. Data were collected from 1 November 2012 to 15 January 2013. A total of 5767 prescriptions were evaluated, 2677 from the institution using CPOE and 3090 from the institution with paper-based prescription. Crude analysis showed an overall risk of a prescription dose error of 1.73 per 100 prescriptions. CPOE resulted in 1.60 and paper-based prescription forms in 1.84 errors per 100 prescriptions, i.e. odds ratio (OR) = 0.87 [95% confidence interval (CI) 0.59–1.29, P = 0.49]. Fifteen different types of errors and four potential risk factors were identified. None of the dose errors resulted in the death of the patient. Non-intercepted prescribing dose errors occurred in <2% of the prescriptions. The parallel CPOE system did not significantly reduce the overall risk of dose errors, and although it reduced the risk of calculation errors, it introduced other errors. Strategies to prevent future prescription errors could usefully focus on integrated computerised systems that can aid dose calculations and reduce transcription errors between databases.


  • Open Access

    Does adding an appended oncology module to the Global Trigger Tool increase its value?

    by Thea Otto Mattsson, Janne Lehmann Knudsen, Kim Brixen, Jørn Herrstedt

    To determine any additional value in the evaluation of safety levels by adding an appended oncology module to the Institute for Healthcare Improvement's Global Trigger Tool (GTT). Comparison of two independent retrospective chart reviews: one review team using the general GTT method and one using the general GTT method plus the appended oncology module on the same inpatient charts. The Department of Clinical Oncology at a Danish University Hospital (1000 beds). All inpatients admitted to the hospital in 2010, n = 3692, biweekly sample of 10 admission charts resulting in a double review of 240 charts. Total number of identified adverse events (AEs), distribution of identified AEs in the harm categories of the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP), AEs per 100 admissions and AEs per 1000 admission days. No significant (95% confidence interval) difference was found between review teams using the general GTT versus the general GTT plus the appended oncology module on the total number of identified AEs, AEs per 100 admissions, AEs per 1000 admission days or in the overall distribution of identified AEs in the five NCC MERP harm categories. The study showed that adding the appended oncology module to the GTT did not increase its value regarding the evaluation of safety levels. This finding could be due to the measurement error of the GTT. Further studies evaluating the measurement properties and the specific additional modules to the general GTT are needed.